Sponsor hub

University of Maryland, Baltimore clinical trial failures

Review 79 stopped clinical trials from University of Maryland, Baltimore, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 1 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials79
Likely biological signals1
Shown below79

Dominant stop reasons

OPERATIONAL
51
OTHER/UNKNOWN
26
REGULATORY
1
SAFETY
1

Notable sponsors

University of Maryland, Baltimore
79

Related phases

Phase II
29
Phase IV
17
Phase I
15
Unknown
11
Early Phase I
4

Crawlable stopped-trial records

Open Explore

Showing up to 79 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT03685253: Nicotinamide Riboside for Diabetic Neuropathy

Phase I Diabetic Neuropathy Peripheral trial by University of Maryland, Baltimore. Stop reason: OPERATIONAL.

Completed the pilot study and grant funding not obtained to continue to the main phase 2 study. The pilot study did not show a statistical significance in the primary or secondary outcome measures.

NCT06447194: Effect of RECK in Posterior Spinal Fusion

Phase I Degenerative Lumbar Spinal Stenosis trial by University of Maryland, Baltimore. Stop reason: OPERATIONAL.

Study was not feasible due to logistical and implementation challenges. No participants were enrolled and the study will not proceed further.

NCT05762744: Pharmacogenomics of GLP1 Receptor Agonists

Phase I Type 2 Diabetes trial by University of Maryland, Baltimore. Stop reason: OPERATIONAL.

We concluded that it would not be possible to meet our recruitment targets within the available budget. The study was ended when the funding ended.

NCT05946811: Macitentan to Prevent PRVO

Phase III Pulmonary Embolism trial by University of Maryland, Baltimore. Stop reason: OPERATIONAL.

Study was cancelled by funding agency before starting enrollment.

NCT03426137: Relieving Acute Pain (RAP) Study: A Pilot Study

Phase II Trauma trial by University of Maryland, Baltimore. Stop reason: OPERATIONAL.

The focus of the project has shifted to publishing a protocol for future trials because we were unable to recruit. Three participants signed the consent forms but withdrew before the randomization.